Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis

Luigi Gennari, Daniela Merlotti, Konstantinos Stolakis, Ranuccio Nuti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Estrogen replacement is traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women as well as for the management of menopausal symptoms. However, estrogen may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter is considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remains uncertain. Hence, there is a need for additional effective medications to prevent fractures in postmenopausal women that provide additional benefits. Areas covered: This article reviews lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis and urogenital atrophy. The medical literature is reviewed for articles containing the terms 'lasofoxifene' and 'SERMs'. The manuscript reviews the discovery strategies and preclinical development of lasofoxifene as well as its clinical development. Expert opinion: Recent evidence suggests that the ideal SERM profile for one patient may be far from ideal for another. Thus, it could be favorable that different SERMs may be available in the future, each with a somewhat different profile that may be rationally applied to various patients with a spectrum of needs. In this context, lasofoxifene, while retaining some of the adverse effects of other SERMs (i.e., hot flushes and risk of venous thromboembolic events), may offer an improved skeletal efficacy over raloxifene, addressing other postmenopausal conditions, including reduction in breast cancer risk and treatment of vaginal atrophy.

Original languageEnglish
Pages (from-to)205-217
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume6
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Selective Estrogen Receptor Modulators
Postmenopausal Osteoporosis
Drug Discovery
Atrophy
Estrogens
Therapeutics
Osteoporotic Fractures
Estrogen Replacement Therapy
Manuscripts
Diphosphonates
Expert Testimony
Progestins
Endometrial Neoplasms
Complementary Therapies
Lasofoxifene
Breast
Breast Neoplasms

Keywords

  • estrogen receptor
  • fractures
  • lasofoxifene
  • menopause
  • postmenopausal osteoporosis
  • SERM

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. / Gennari, Luigi; Merlotti, Daniela; Stolakis, Konstantinos; Nuti, Ranuccio.

In: Expert Opinion on Drug Discovery, Vol. 6, No. 2, 02.2011, p. 205-217.

Research output: Contribution to journalArticle

Gennari, Luigi ; Merlotti, Daniela ; Stolakis, Konstantinos ; Nuti, Ranuccio. / Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. In: Expert Opinion on Drug Discovery. 2011 ; Vol. 6, No. 2. pp. 205-217.
@article{5b0043a1b5804f3f925eea4356552fa5,
title = "Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis",
abstract = "Introduction: Estrogen replacement is traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women as well as for the management of menopausal symptoms. However, estrogen may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter is considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remains uncertain. Hence, there is a need for additional effective medications to prevent fractures in postmenopausal women that provide additional benefits. Areas covered: This article reviews lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis and urogenital atrophy. The medical literature is reviewed for articles containing the terms 'lasofoxifene' and 'SERMs'. The manuscript reviews the discovery strategies and preclinical development of lasofoxifene as well as its clinical development. Expert opinion: Recent evidence suggests that the ideal SERM profile for one patient may be far from ideal for another. Thus, it could be favorable that different SERMs may be available in the future, each with a somewhat different profile that may be rationally applied to various patients with a spectrum of needs. In this context, lasofoxifene, while retaining some of the adverse effects of other SERMs (i.e., hot flushes and risk of venous thromboembolic events), may offer an improved skeletal efficacy over raloxifene, addressing other postmenopausal conditions, including reduction in breast cancer risk and treatment of vaginal atrophy.",
keywords = "estrogen receptor, fractures, lasofoxifene, menopause, postmenopausal osteoporosis, SERM",
author = "Luigi Gennari and Daniela Merlotti and Konstantinos Stolakis and Ranuccio Nuti",
year = "2011",
month = "2",
doi = "10.1517/17460441.2011.547188",
language = "English",
volume = "6",
pages = "205--217",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis

AU - Gennari, Luigi

AU - Merlotti, Daniela

AU - Stolakis, Konstantinos

AU - Nuti, Ranuccio

PY - 2011/2

Y1 - 2011/2

N2 - Introduction: Estrogen replacement is traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women as well as for the management of menopausal symptoms. However, estrogen may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter is considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remains uncertain. Hence, there is a need for additional effective medications to prevent fractures in postmenopausal women that provide additional benefits. Areas covered: This article reviews lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis and urogenital atrophy. The medical literature is reviewed for articles containing the terms 'lasofoxifene' and 'SERMs'. The manuscript reviews the discovery strategies and preclinical development of lasofoxifene as well as its clinical development. Expert opinion: Recent evidence suggests that the ideal SERM profile for one patient may be far from ideal for another. Thus, it could be favorable that different SERMs may be available in the future, each with a somewhat different profile that may be rationally applied to various patients with a spectrum of needs. In this context, lasofoxifene, while retaining some of the adverse effects of other SERMs (i.e., hot flushes and risk of venous thromboembolic events), may offer an improved skeletal efficacy over raloxifene, addressing other postmenopausal conditions, including reduction in breast cancer risk and treatment of vaginal atrophy.

AB - Introduction: Estrogen replacement is traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women as well as for the management of menopausal symptoms. However, estrogen may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter is considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remains uncertain. Hence, there is a need for additional effective medications to prevent fractures in postmenopausal women that provide additional benefits. Areas covered: This article reviews lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis and urogenital atrophy. The medical literature is reviewed for articles containing the terms 'lasofoxifene' and 'SERMs'. The manuscript reviews the discovery strategies and preclinical development of lasofoxifene as well as its clinical development. Expert opinion: Recent evidence suggests that the ideal SERM profile for one patient may be far from ideal for another. Thus, it could be favorable that different SERMs may be available in the future, each with a somewhat different profile that may be rationally applied to various patients with a spectrum of needs. In this context, lasofoxifene, while retaining some of the adverse effects of other SERMs (i.e., hot flushes and risk of venous thromboembolic events), may offer an improved skeletal efficacy over raloxifene, addressing other postmenopausal conditions, including reduction in breast cancer risk and treatment of vaginal atrophy.

KW - estrogen receptor

KW - fractures

KW - lasofoxifene

KW - menopause

KW - postmenopausal osteoporosis

KW - SERM

UR - http://www.scopus.com/inward/record.url?scp=79251504654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251504654&partnerID=8YFLogxK

U2 - 10.1517/17460441.2011.547188

DO - 10.1517/17460441.2011.547188

M3 - Article

VL - 6

SP - 205

EP - 217

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 2

ER -